Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.
top of page
Search
Recent Posts
See AllNuvOx Announces Two New Publications Tucson, AZ – October 21, 2024 - Co-Founders, Dr. Evan Unger and Dr. Jennifer LH Johnson combine...
Tucson, AZ – October 9, 2024 - Dr. Evan Unger, Executive Chairman of NuvOx Therapeutics (NuvOx), has been awarded the 2024 Harry Fischer...
Tucson, AZ, September 6th, 2024 – NuvOx Pharma LLC, a wholly owned subsidiary of NuvOx Therapeutics Inc. (together, “NuvOx”) announced...
bottom of page
コメント